Public seminar

with Professor Gareth Evans

21 February 2023

A global perspective on the current methods of breast cancer screening and the potential benefits of a more personalised approach.

Lecture, panel discussion and Q&A session

Globally, the current breast cancer screening approach saves hundreds of thousands of lives every year but it’s not without downsides for women and health systems. Is there a better way?

Join international and local experts for a special presentation: ‘Should we move to risk-adapted breast screening?’.  This special public lecture will examine current methods of breast cancer screening around the world and look at the potential benefits of moving towards a more personalised approach.

Keynote speaker

Professor Gareth Evans
Consultant, Manchester University Hospitals NHS Foundation Trust and The Christie NHS Foundation

• What are the limitations of traditional mammography screening?

• An introduction to the concept of risk-adapted screening: what it means and potential for early detection

• Concerns and challenges of implementing risk-adapted screening

• Benefits of a risk-adapted screening program

Panel discussion

Hosted by:

Professor Bruce Mann
VCCC Alliance Research & Education Lead, Breast Cancer, Director of the Breast Cancer Tumour Stream and Consultant Surgeon, Peter MacCallum Cancer Centre

• Can risk-adapted screening improve patient outcomes and offer better personalised care for individuals at different levels of risks

• Considerations for Australian health services and populations

There will also be an opportunity for audience members to ask questions and comment.

Professor Gareth Evans

Professor Gareth Evans is a Consultant at Manchester University Hospitals NHS Foundation Trust and The Christie NHS Foundation Trust, UK. He has established a national and international reputation in clinical and research aspects of cancer genetics, particularly in neurofibromatosis, schwannomatosis and breast cancer. Professor Evans is a chair of medical genetics and cancer epidemiology at the University of Manchester. He has published 1002 peer-reviewed original research publications, 350 as first or senior author and in addition, over 160 reviews, chapters and letters. He has a Web of Science H-index of 127 and a Google Scholar of 168.

In the last ten years, he has raised over £80 million in grants for multicentre and local studies. He is Chief Investigator on two NIHR program grants on breast cancer risk prediction and also has an NIHR RfPB grant as CI (2011). He has led a successful bid for a Nationally funded NF2 service (£7.5 million pa) that started in 2010 and is involved in the national complex NF1 service. He is the cancer prevention early detection theme leader at the NIHR Manchester Biomedical Research Centre. Professor Evans is also lead clinician on the NICE Familial Breast Cancer Guideline Group and is a trustee of NF2Biosolutions and former for Breast Cancer Now and the Neuro Foundation. He has been lead or senior author on three guidelines for the management of TP53-related cancer syndrome (LFS).